Prostate cancer in 2011: Hitting old targets better and identifying new targets Journal Article
| Authors: | Chen, Y.; Scher, H. I. |
| Article Title: | Prostate cancer in 2011: Hitting old targets better and identifying new targets |
| Keywords: | cancer survival; unclassified drug; overall survival; prednisone; review; placebo; cancer combination chemotherapy; drug efficacy; drug safety; clinical trials as topic; drug approval; bone metastasis; cancer radiotherapy; outcome assessment; prostate specific antigen; cancer screening; history, 21st century; bone pain; antineoplastic activity; dasatinib; high risk patient; docetaxel; prostatic neoplasms; early diagnosis; prostatectomy; radiopharmaceutical agent; abiraterone acetate; zoledronic acid; bone disease; castration resistant prostate cancer; molecularly targeted therapy; denosumab; molecular targeted therapy; radium 223; 4 [3 [4 cyano 3 (trifluoromethyl)phenyl] 5,5 dimethyl 4 oxo 2 thioxo 1 imidazolidinyl] 2 fluoro n methylbenzamide; cabazitaxel; sipuleucel t; cabozantinib |
| Journal Title: | Nature Reviews Clinical Oncology |
| Volume: | 9 |
| Issue: | 2 |
| ISSN: | 1759-4774 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2012-01-10 |
| Start Page: | 70 |
| End Page: | 72 |
| Language: | English |
| DOI: | 10.1038/nrclinonc.2011.213 |
| PROVIDER: | scopus |
| PUBMED: | 22231760 |
| PMCID: | PMC5572096 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 March 2012" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work